Event info
Date:26 Nov
Time:10:00 - 11:00
Venue:Online
Contact person
Nicole Mastrell

Nicole Mastrell

Event Manager & PA to CEO

nm@mva.org

+45 6141 8634

Early Drug Development: Strategy and Solution

This webinar will focus on the key considerations for transitioning small molecules from preclinical through clinical development. Experts will discuss the technological aspects of drug development and describe practical approaches to improve bioavailability of poorly soluble drugs.

In addition, the speakers will discuss the ways physiologically based pharmacokinetic (PBPK) models are used to predict the pharmacokinetics (PK) of drugs to support drug design study. Recent advances in vivo and ex vivo models used in preclinical studies of drug development will also be discussed.

Date: November 26, 2020
Time: 10:00 – 11:30 CET
Venue: Online

READ MORE & SIGN UP

Program

The Importance of Clinically-Relevant Preclinical Models in Drug Development
Anna Grabowska
Professor of Cancer Microenvironment, University of Nottingham

  • Recent advances in vivo and ex vivo models in preclinical studies, including models using close-to-patient cells and incorporating stromal cells
  • Why the 3D cultures are more relevant cell cultures compared to the 2D models
  • How the 3D cultures are used for the discovery of new drug candidates
Early Drug Development Considerations: Strategies and Practice
Stephen Tindal
Director, Science & Technology, Catalent

  • Molecule developability assessment and key testing strategies to determine the potential of the molecule
  • Solubility and bioavailability challenges and formulation approaches to mitigate them
Integrating In Silico, In Vitro and In Vivo Data with PBPK Modeling for Improved Formulation Development
Jan Neelissen, Ph.D.
Scientific Advisor, Science & Technology, Catalent

  • Identifying key ADME attributes & input parameters for PBPK modeling
  • PBPK modeling approaches in molecule lead selection
  • PBPK modeling for the prediction of human PK

 

Organizers

Co-organized between Life Science Sweden and Catalent